logo
Plus   Neg
Share
Email

Merck: KEYTRUDA Approved For New Indication In China - Quick Facts

Merck (MRK) said KEYTRUDA, the company's anti-PD-1 therapy, has been approved by the National Medical Products Administration in China as monotherapy for the treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 as determined by a fully validated test, following failure of one prior line of systemic therapy. The company noted that, with the new approval, KEYTRUDA is now approved for five indications across three different types of cancer in China.

Separately, Merck reported results from two initial Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company's investigational 15-valent pneumococcal conjugate vaccine. The company said V114 met safety and immunogenicity objectives in initial phase 3 studies in adults. The company plans to continue to work with the FDA and other regulatory authorities around the world on filing plans for licensure of this vaccine as more data from the Phase 3 program become available.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT